JP2008503523A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008503523A5 JP2008503523A5 JP2007517174A JP2007517174A JP2008503523A5 JP 2008503523 A5 JP2008503523 A5 JP 2008503523A5 JP 2007517174 A JP2007517174 A JP 2007517174A JP 2007517174 A JP2007517174 A JP 2007517174A JP 2008503523 A5 JP2008503523 A5 JP 2008503523A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridin
- corresponding hydrochloride
- dimethylaminomethyl
- amine
- ylmethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 30
- 208000002193 Pain Diseases 0.000 claims description 28
- 238000011282 treatment Methods 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 10
- 208000019901 Anxiety disease Diseases 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 6
- 206010013663 drug dependence Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 208000017520 skin disease Diseases 0.000 claims description 6
- 208000011117 substance-related disease Diseases 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 208000032841 Bulimia Diseases 0.000 claims description 5
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 5
- 208000030814 Eating disease Diseases 0.000 claims description 5
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 5
- 208000001640 Fibromyalgia Diseases 0.000 claims description 5
- 208000019695 Migraine disease Diseases 0.000 claims description 5
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 5
- 208000003251 Pruritus Diseases 0.000 claims description 5
- 208000028017 Psychotic disease Diseases 0.000 claims description 5
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 5
- 208000016620 Tourette disease Diseases 0.000 claims description 5
- 206010046543 Urinary incontinence Diseases 0.000 claims description 5
- 208000010877 cognitive disease Diseases 0.000 claims description 5
- 235000014632 disordered eating Nutrition 0.000 claims description 5
- 206010027599 migraine Diseases 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 3
- 208000013403 hyperactivity Diseases 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 29
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 229910052794 bromium Inorganic materials 0.000 claims 4
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 229910052740 iodine Inorganic materials 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- CYHKDODPXAVVJY-UHFFFAOYSA-N 1-(5-methoxy-1-pyridin-3-yl-3,4-dihydronaphthalen-2-yl)-n,n-dimethylmethanamine Chemical compound CN(C)CC=1CCC=2C(OC)=CC=CC=2C=1C1=CC=CN=C1 CYHKDODPXAVVJY-UHFFFAOYSA-N 0.000 claims 2
- JKUVGEXRZZWOFY-UHFFFAOYSA-N 1-(6-fluoro-3-pyridin-3-yl-1h-inden-2-yl)-n,n-dimethylmethanamine Chemical compound C12=CC=C(F)C=C2CC(CN(C)C)=C1C1=CC=CN=C1 JKUVGEXRZZWOFY-UHFFFAOYSA-N 0.000 claims 2
- GQPGBYGEQXBPQQ-UHFFFAOYSA-N 1-(6-methoxy-3-pyridin-3-yl-1h-inden-2-yl)-n,n-dimethylmethanamine Chemical compound CN(C)CC=1CC2=CC(OC)=CC=C2C=1C1=CC=CN=C1 GQPGBYGEQXBPQQ-UHFFFAOYSA-N 0.000 claims 2
- AYIMCOMVIZKFTL-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-pyridin-3-yl-2,3-dihydroinden-1-ol Chemical compound CN(C)CC1CC2=CC=CC=C2C1(O)C1=CC=CN=C1 AYIMCOMVIZKFTL-UHFFFAOYSA-N 0.000 claims 2
- CJZGNRDVLLHEER-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-pyridin-3-yl-3h-inden-5-ol Chemical compound C12=CC=C(O)C=C2CC(CN(C)C)=C1C1=CC=CN=C1 CJZGNRDVLLHEER-UHFFFAOYSA-N 0.000 claims 2
- QRKAPEZZSALFQR-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-5-methoxy-1-pyridin-3-yl-3,4-dihydro-2h-naphthalen-1-ol Chemical compound COC1=CC=CC2=C1CCC(CN(C)C)C2(O)C1=CC=CN=C1 QRKAPEZZSALFQR-UHFFFAOYSA-N 0.000 claims 2
- JRQUDCPZCIGPEF-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-6-methoxy-1-pyridin-3-yl-2,3-dihydroinden-1-ol Chemical compound C12=CC(OC)=CC=C2CC(CN(C)C)C1(O)C1=CC=CN=C1 JRQUDCPZCIGPEF-UHFFFAOYSA-N 0.000 claims 2
- GDMQXYMWMGHHKE-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-4-pyridin-3-yl-2,3-dihydrochromen-4-ol Chemical compound CN(C)CC1COC2=CC=CC=C2C1(O)C1=CC=CN=C1 GDMQXYMWMGHHKE-UHFFFAOYSA-N 0.000 claims 2
- AHCCCKGSLZERRE-UHFFFAOYSA-N 4-[(dimethylamino)methyl]-5-pyridin-3-yl-3,4-dihydro-2h-1-benzoxepin-5-ol Chemical compound CN(C)CC1CCOC2=CC=CC=C2C1(O)C1=CC=CN=C1 AHCCCKGSLZERRE-UHFFFAOYSA-N 0.000 claims 2
- AZFNLAWLWJOLDL-UHFFFAOYSA-N 6-[(dimethylamino)methyl]-5-pyridin-3-yl-6,7,8,9-tetrahydrobenzo[7]annulen-5-ol Chemical compound CN(C)CC1CCCC2=CC=CC=C2C1(O)C1=CC=CN=C1 AZFNLAWLWJOLDL-UHFFFAOYSA-N 0.000 claims 2
- 229910052744 lithium Inorganic materials 0.000 claims 2
- YGCWTLJXPQFPEQ-UHFFFAOYSA-N n,n-dimethyl-1-(3-pyridin-3-yl-1h-inden-2-yl)methanamine Chemical compound C12=CC=CC=C2CC(CN(C)C)=C1C1=CC=CN=C1 YGCWTLJXPQFPEQ-UHFFFAOYSA-N 0.000 claims 2
- LAHZKUNEQKCMJZ-UHFFFAOYSA-N n,n-dimethyl-1-(5-pyridin-3-yl-8,9-dihydro-7h-benzo[7]annulen-6-yl)methanamine Chemical compound C12=CC=CC=C2CCCC(CN(C)C)=C1C1=CC=CN=C1 LAHZKUNEQKCMJZ-UHFFFAOYSA-N 0.000 claims 2
- VQEYEIUTACZWBP-UHFFFAOYSA-N n,n-dimethyl-1-[3-pyridin-3-yl-6-(trifluoromethoxy)-1h-inden-2-yl]methanamine Chemical compound C12=CC=C(OC(F)(F)F)C=C2CC(CN(C)C)=C1C1=CC=CN=C1 VQEYEIUTACZWBP-UHFFFAOYSA-N 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims 2
- VSNLINZDYNIUSB-UHFFFAOYSA-N 1-(5-methoxy-3-pyridin-3-yl-1h-inden-2-yl)-n,n-dimethylmethanamine Chemical compound C12=CC(OC)=CC=C2CC(CN(C)C)=C1C1=CC=CN=C1 VSNLINZDYNIUSB-UHFFFAOYSA-N 0.000 claims 1
- PWFIDZRWWJSWEM-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-pyridin-3-yl-3,4-dihydro-2h-naphthalen-1-ol Chemical compound CN(C)CC1CCC2=CC=CC=C2C1(O)C1=CC=CN=C1 PWFIDZRWWJSWEM-UHFFFAOYSA-N 0.000 claims 1
- PRPULZAHTDWDFW-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-pyridin-3-yl-5-(trifluoromethoxy)-2,3-dihydroinden-1-ol Chemical compound CN(C)CC1CC2=CC(OC(F)(F)F)=CC=C2C1(O)C1=CC=CN=C1 PRPULZAHTDWDFW-UHFFFAOYSA-N 0.000 claims 1
- INBQRBCPBDIRFT-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-pyridin-3-yl-5-(trifluoromethyl)-2,3-dihydroinden-1-ol Chemical compound CN(C)CC1CC2=CC(C(F)(F)F)=CC=C2C1(O)C1=CC=CN=C1 INBQRBCPBDIRFT-UHFFFAOYSA-N 0.000 claims 1
- YEENLRKTQJLHGC-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-5-fluoro-1-pyridin-3-yl-2,3-dihydroinden-1-ol Chemical compound CN(C)CC1CC2=CC(F)=CC=C2C1(O)C1=CC=CN=C1 YEENLRKTQJLHGC-UHFFFAOYSA-N 0.000 claims 1
- HSQDHZQNMRYXIH-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-5-methoxy-1-pyridin-3-yl-2,3-dihydroinden-1-ol Chemical compound C=1C(OC)=CC=C2C=1CC(CN(C)C)C2(O)C1=CC=CN=C1 HSQDHZQNMRYXIH-UHFFFAOYSA-N 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- 229930040373 Paraformaldehyde Natural products 0.000 claims 1
- KMKLUVYHNKQOSE-UHFFFAOYSA-N [Ce+2] Chemical compound [Ce+2] KMKLUVYHNKQOSE-UHFFFAOYSA-N 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 238000006555 catalytic reaction Methods 0.000 claims 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 150000002366 halogen compounds Chemical class 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- ZIKZSXHMGBOHMR-UHFFFAOYSA-N n,n-dimethyl-1-(1-pyridin-3-yl-1,2,3,4-tetrahydronaphthalen-2-yl)methanamine Chemical compound CN(C)CC1CCC2=CC=CC=C2C1C1=CC=CN=C1 ZIKZSXHMGBOHMR-UHFFFAOYSA-N 0.000 claims 1
- AAMBJVCFOBUEQZ-UHFFFAOYSA-N n,n-dimethyl-1-(1-pyridin-3-yl-2,3-dihydro-1h-inden-2-yl)methanamine Chemical compound CN(C)CC1CC2=CC=CC=C2C1C1=CC=CN=C1 AAMBJVCFOBUEQZ-UHFFFAOYSA-N 0.000 claims 1
- QVNAEAOVUDUJDB-UHFFFAOYSA-N n,n-dimethyl-1-(1-pyridin-3-yl-3,4-dihydronaphthalen-2-yl)methanamine Chemical compound C12=CC=CC=C2CCC(CN(C)C)=C1C1=CC=CN=C1 QVNAEAOVUDUJDB-UHFFFAOYSA-N 0.000 claims 1
- MVFSHUNZGXRRAO-UHFFFAOYSA-N n,n-dimethyl-1-(4-pyridin-3-yl-2h-chromen-3-yl)methanamine Chemical compound C12=CC=CC=C2OCC(CN(C)C)=C1C1=CC=CN=C1 MVFSHUNZGXRRAO-UHFFFAOYSA-N 0.000 claims 1
- CRILCMHJXQMVLZ-UHFFFAOYSA-N n,n-dimethyl-1-(5-pyridin-3-yl-2,3-dihydro-1-benzoxepin-4-yl)methanamine Chemical compound C12=CC=CC=C2OCCC(CN(C)C)=C1C1=CC=CN=C1 CRILCMHJXQMVLZ-UHFFFAOYSA-N 0.000 claims 1
- CPRVRYUDZUPTAT-UHFFFAOYSA-N n,n-dimethyl-1-[3-pyridin-3-yl-6-(trifluoromethyl)-1h-inden-2-yl]methanamine Chemical compound C12=CC=C(C(F)(F)F)C=C2CC(CN(C)C)=C1C1=CC=CN=C1 CPRVRYUDZUPTAT-UHFFFAOYSA-N 0.000 claims 1
- 150000002902 organometallic compounds Chemical class 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 229920002866 paraformaldehyde Polymers 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- AEVWRTLZSNHCLK-UHFFFAOYSA-N thiepin-4-ol Chemical compound OC1=CC=CSC=C1 AEVWRTLZSNHCLK-UHFFFAOYSA-N 0.000 claims 1
- 208000002271 trichotillomania Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 description 11
- 208000020925 Bipolar disease Diseases 0.000 description 9
- 206010026749 Mania Diseases 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
- 208000020401 Depressive disease Diseases 0.000 description 4
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 4
- 206010021030 Hypomania Diseases 0.000 description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 4
- 208000005298 acute pain Diseases 0.000 description 4
- 229960002748 norepinephrine Drugs 0.000 description 4
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000028698 Cognitive impairment Diseases 0.000 description 3
- 206010012218 Delirium Diseases 0.000 description 3
- 208000011688 Generalised anxiety disease Diseases 0.000 description 3
- 206010065390 Inflammatory pain Diseases 0.000 description 3
- 206010034912 Phobia Diseases 0.000 description 3
- 206010041250 Social phobia Diseases 0.000 description 3
- 208000028683 bipolar I disease Diseases 0.000 description 3
- 208000025307 bipolar depression Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000029364 generalized anxiety disease Diseases 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 206010027175 memory impairment Diseases 0.000 description 3
- 230000003040 nociceptive effect Effects 0.000 description 3
- 208000019906 panic disease Diseases 0.000 description 3
- 208000022821 personality disease Diseases 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 206010010305 Confusional state Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 2
- 206010038678 Respiratory depression Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000407 monoamine reuptake Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 208000019899 phobic disease Diseases 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 208000020685 sleep-wake disease Diseases 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 101001122476 Homo sapiens Mu-type opioid receptor Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 102100028647 Mu-type opioid receptor Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010040108 Serotonin syndrome Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 239000002623 mu opiate receptor antagonist Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000000966 norepinephrine reuptake Effects 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 201000001716 specific phobia Diseases 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004030099A DE102004030099A1 (de) | 2004-06-22 | 2004-06-22 | Gesättigte und ungesättigte 3-Pyridyl-benzocycloalkylmethyl-amine als Serotonin- und/oder Noradrenalin-Reuptake-Hemmer und/oder µ-Opioidrezeptor-Modulatoren |
| DE102004030099.2 | 2004-06-22 | ||
| PCT/EP2005/006624 WO2005123681A1 (de) | 2004-06-22 | 2005-06-20 | Gesättigte und ungesättigte 3-pyridyl-benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008503523A JP2008503523A (ja) | 2008-02-07 |
| JP2008503523A5 true JP2008503523A5 (OSRAM) | 2011-12-22 |
| JP4918486B2 JP4918486B2 (ja) | 2012-04-18 |
Family
ID=35106829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007517174A Expired - Fee Related JP4918486B2 (ja) | 2004-06-22 | 2005-06-20 | 苦痛、うつ病及び（又は）不安障害の治療に使用するための飽和及び不飽和３−ピリジル−ベンゾシクロアルキルメチル−アミン類 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8278338B2 (OSRAM) |
| EP (1) | EP1758860B1 (OSRAM) |
| JP (1) | JP4918486B2 (OSRAM) |
| AT (1) | ATE441632T1 (OSRAM) |
| CA (1) | CA2568897C (OSRAM) |
| CY (1) | CY1109519T1 (OSRAM) |
| DE (2) | DE102004030099A1 (OSRAM) |
| DK (1) | DK1758860T3 (OSRAM) |
| ES (1) | ES2333976T3 (OSRAM) |
| PL (1) | PL1758860T3 (OSRAM) |
| PT (1) | PT1758860E (OSRAM) |
| SI (1) | SI1758860T1 (OSRAM) |
| WO (1) | WO2005123681A1 (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7435837B2 (en) | 2003-10-24 | 2008-10-14 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
| CA2604915A1 (en) | 2005-04-22 | 2006-11-02 | Wyeth | New therapeutic combinations for the treatment or prevention of depression |
| WO2007081542A2 (en) * | 2006-01-06 | 2007-07-19 | Sepracor Inc. | Tetralone-based monoamine reuptake inhibitors |
| ES2397764T3 (es) | 2008-04-01 | 2013-03-11 | Abbott Gmbh & Co. Kg | Tetrahidroisoquinolinas, composiciones farmacéuticas que las contienen, y su uso en terapia |
| AR075442A1 (es) | 2009-02-16 | 2011-03-30 | Abbott Gmbh & Co Kg | Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia |
| US8877794B2 (en) | 2010-08-13 | 2014-11-04 | Abbott Laboratories | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9051280B2 (en) | 2010-08-13 | 2015-06-09 | AbbVie Deutschland GmbH & Co. KG | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9045459B2 (en) | 2010-08-13 | 2015-06-02 | AbbVie Deutschland GmbH & Co. KG | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8883839B2 (en) | 2010-08-13 | 2014-11-11 | Abbott Laboratories | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8846743B2 (en) | 2010-08-13 | 2014-09-30 | Abbott Laboratories | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9309200B2 (en) | 2011-05-12 | 2016-04-12 | AbbVie Deutschland GmbH & Co. KG | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8853196B2 (en) | 2011-08-05 | 2014-10-07 | AbbVie Deutschland GmbH & Co. KG | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| CA2853254A1 (en) | 2011-11-18 | 2013-05-23 | Abbvie Inc. | N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9650334B2 (en) | 2013-03-15 | 2017-05-16 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9656955B2 (en) | 2013-03-15 | 2017-05-23 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9643947B2 (en) | 2013-08-28 | 2017-05-09 | Northwestern University | 7-membered fused heterocycles and methods of their synthesis |
| CA2924699A1 (en) | 2013-10-17 | 2015-04-23 | AbbVie Deutschland GmbH & Co. KG | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| MX2016004936A (es) | 2013-10-17 | 2016-12-20 | Abbvie Deutschland | Derivados de aminocromano, aminotiocromano y amino-1,2,3,4-tetrahi droquinilina, composiciones farmaceuticas que los contienen, y su uso en terapia. |
| CN104844471B (zh) * | 2015-04-21 | 2017-05-03 | 苏州远智医药科技有限公司 | 一种作为dor受体拮抗剂的化合物 |
| CN109896991B (zh) * | 2017-12-08 | 2020-11-20 | 苏州远智医药科技有限公司 | 一种δ阿片受体拮抗剂及其用途和药物组合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3444176A (en) * | 1967-04-28 | 1969-05-13 | Mcneilab Inc | Certain 4-diloweralkylamino-lower alkyl - 5 - pyridyl (or phenyl)-2,3-dihydro - 1 - benzothiepins and derivatives thereof |
| US4845221A (en) * | 1988-04-15 | 1989-07-04 | American Home Products Corporation | Serotonergic substituted piperazinyl tetralins |
| AU648359B2 (en) * | 1990-11-22 | 1994-04-21 | Janssen Pharmaceutica N.V. | Isonicotinic acid derivatives |
| US5668141A (en) * | 1996-04-02 | 1997-09-16 | Abbott Laboratories | Trans-2,6-,3,6-and 4,6-diaza-5,6,6a,7,8,12b-hexahydrobenzo[c]phenanthrene compounds as dopamine agonists |
| DE19805370A1 (de) * | 1997-03-14 | 1998-09-17 | Gruenenthal Gmbh | Substituierte Aminoverbindungen und ihre Verwendung als analgetisch wirksame Substanzen |
| AU4037699A (en) * | 1998-05-08 | 1999-11-29 | Akzo Nobel N.V. | Novel aryl-hydro naphthalenal kanamines |
| TW555757B (en) * | 1998-07-31 | 2003-10-01 | Akzo Nobel Nv | Aminomethylcarboxylic acid derivatives |
| CO5271697A1 (es) * | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona |
| JP4612990B2 (ja) * | 2001-03-16 | 2011-01-12 | アボット・ラボラトリーズ | ヒスタミン−３受容体リガンドとしての新規アミンおよびそれらの治療的適用 |
| CA2452596C (en) * | 2001-07-05 | 2010-12-21 | Takeda Chemical Industries, Ltd. | Benzo-fused 5-membered heterocyclic compounds, their production and use |
| JP2004149429A (ja) * | 2002-10-29 | 2004-05-27 | Takeda Chem Ind Ltd | インドール化合物およびその用途 |
-
2004
- 2004-06-22 DE DE102004030099A patent/DE102004030099A1/de not_active Withdrawn
-
2005
- 2005-06-20 JP JP2007517174A patent/JP4918486B2/ja not_active Expired - Fee Related
- 2005-06-20 PL PL05766092T patent/PL1758860T3/pl unknown
- 2005-06-20 ES ES05766092T patent/ES2333976T3/es not_active Expired - Lifetime
- 2005-06-20 EP EP05766092A patent/EP1758860B1/de not_active Expired - Lifetime
- 2005-06-20 WO PCT/EP2005/006624 patent/WO2005123681A1/de not_active Ceased
- 2005-06-20 AT AT05766092T patent/ATE441632T1/de active
- 2005-06-20 DK DK05766092T patent/DK1758860T3/da active
- 2005-06-20 PT PT05766092T patent/PT1758860E/pt unknown
- 2005-06-20 SI SI200530854T patent/SI1758860T1/sl unknown
- 2005-06-20 CA CA2568897A patent/CA2568897C/en not_active Expired - Fee Related
- 2005-06-20 DE DE502005008058T patent/DE502005008058D1/de not_active Expired - Lifetime
-
2006
- 2006-12-22 US US11/643,792 patent/US8278338B2/en not_active Expired - Fee Related
-
2009
- 2009-11-30 CY CY20091101251T patent/CY1109519T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008503523A5 (OSRAM) | ||
| JP2010539120A5 (OSRAM) | ||
| JP4918486B2 (ja) | 苦痛、うつ病及び（又は）不安障害の治療に使用するための飽和及び不飽和３−ピリジル−ベンゾシクロアルキルメチル−アミン類 | |
| CN104955826B (zh) | 可用于治疗神经学疾病和病症的螺-喹唑酮衍生物 | |
| CN111712247B (zh) | sGC刺激剂 | |
| MX2012007409A (es) | Derivados de benzamida sustituidos. | |
| JP2010539121A5 (OSRAM) | ||
| TW200738645A (en) | Use of 4-imidazole derivatives for CNS disorders | |
| JP2004518763A5 (OSRAM) | ||
| JP2004534816A5 (OSRAM) | ||
| JP2011517443A5 (OSRAM) | ||
| JP2002508364A (ja) | セロトニン１ａ受容体に対して活性を有するアリールピペラジン | |
| JP2005508872A5 (OSRAM) | ||
| JP2016023188A (ja) | 神経突起伸長の促進におけるナノ金属の使用および神経障害の処置および／または予防 | |
| JP2017512211A (ja) | アミノカルボニルカルバメート化合物 | |
| JP2005517036A5 (OSRAM) | ||
| CN101088498B (zh) | 补骨脂酚类化合物的应用 | |
| MX2010009643A (es) | Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a). | |
| BRPI0613491A2 (pt) | antagonistas de piperazina-piperidina e agonistas do receptor de 5-ht1a | |
| JP5600253B2 (ja) | 情動障害の治療のための［２−（６−フルオロ−１ｈ−インドール−３−イルスルファニル）ベンジル］メチルアミン | |
| JP2018508556A5 (OSRAM) | ||
| CN1284056A (zh) | 抗惊厥和中枢神经系统活性的双(氟苯基)烷基酰胺 | |
| JP2012512251A5 (OSRAM) | ||
| AU2001255654B2 (en) | Materials and methods for the treatment of depression | |
| TW201124139A (en) | Solid forms of 4-{(R)-(3-aminophenyl)[4-(4-fluorobenzyl)piperazin-1-yl]methyl}-n, n-diethylbenzamide, compositions thereof, and uses therewith |